Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858816 | 0.83 | FFAR3 (0.36) | TDP1TP53CYP1A2 | |
| SCHEMBL14055633 | 0.83 | FFAR3 (0.36) | TDP1TP53CYP1A2 | |
| SCHEMBL18229248 | 0.81 | FFAR3 (0.35) | TDP1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL109328 | 0.81 | FFAR3 (0.35) | TDP1TP53CYP1A2 | |
| SCHEMBL2188587 | 0.79 | CHRNB2 (0.36) | ALDH1A1TP53 | |
| SCHEMBL10044465 | 0.77 | — | — | |
| SCHEMBL6135565 | 0.75 | — | — | |
| SCHEMBL11997982 | 0.75 | — | — | |
| SCHEMBL18980132 | 0.75 | — | — | |
| SCHEMBL25089429 | 0.73 | ALDH1A1 (0.36) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | ALDH1A1 3837/4885TDP1 1203/4885TP53 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.